pharmaphorum

NOVEMBER 23, 2021

GSK’s head of research, John Lepore, said there is “compelling genetic evidence” showing that reduced HSD17B13 function confers protection to the liver from inflammatory injury that is a characteristic of NASH. Arrowhead said the partnering process for ARO-HSD was competitive and GSK was one of several suitors for the drug.

Sales 52

Sales Drugs Trials RNA 52

Pharmaceutical Technology

FEBRUARY 13, 2023

Gene therapies are an attractive way of targeting the underlying genetic mutations, but traditional approaches cannot be used while targeting mutations for Dravet Syndrome, forcing researchers to develop new ways. Meanwhile, others are researching the link between gene variation and different responses to treatments.

Research 264

Research Gene Gene Therapy Genome 264

XTalks

MARCH 28, 2024

Duvyzat, a histone deacetylase (HDAC) inhibitor that works to reduce inflammation and muscle loss, is the first nonsteroidal drug approved to treat patients with all genetic variants of DMD. Progressive muscle weakness in the disease is caused by genetic mutations in the dystrophin gene that lead to a lack of functional dystrophin protein.

FDA Approval 105

FDA Approval Genetics Gene Therapy Gene 105

pharmaphorum

JANUARY 29, 2021

Since Macrae joined the company just four years ago, Sangamo has more than tripled its staff and raised $1.6 It has also built its own manufacturing site and launched partnerships with six big pharma companies. And ultimately we will be able to add genetic influences to diseases that don’t have a genetic cause.

Gene Editing 145

Gene Editing Gene Gene Therapy In-Vivo 145

Delveinsight

AUGUST 6, 2020

Transthyretin (TTR) is a protein that the liver produces to facilitate the transfer of thyroid hormone and vitamin A in the blood. However, due to specific reasons, the TTR protein begins to misfold and aggregate as fibrils, a process known as amyloidosis of Transthyretin (ATTR). hATTR Market: Present Treatment Options.

Protein 52

Protein Gene Silencing Marketing Gene 52

pharmaphorum

SEPTEMBER 18, 2020

But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.

Pharma Companies 116

Pharma Companies Sales Vaccination Vaccine 116

Roots Analysis

AUGUST 13, 2024

Messenger ribonucleic acid (mRNA) is a type of single-stranded ribonucleic acid (RNA), which helps in transferring genetic information in order to produce proteins. Additionally, the companies are evaluating various mRNA delivery technologies in order to ensure efficient and safe delivery of mRNA-based drugs.

Vaccination 40

Vaccination Vaccine Manufacturing Protein 40

Delveinsight

FEBRUARY 12, 2021

Furthermore, GlaxoSmithKline is developing GSK3377794 (NY-ESO-1 T-cells; GSK ‘794), a NY-ESO-1-directed genetically modified autologous T-cell immunotherapy and is an engineered T-cell therapy. Genetic counseling and other symptomatic treatment also help. Argininosuccinic aciduria is a rare disease that is genetically inherited.

Marketing 52

Marketing Clinical Trials Clinical Trials Development 52

XTalks

DECEMBER 13, 2023

Now, let’s delve into the list of the top ten fastest growing biotech companies in 2023, ranked by their compound annual growth rate (CAGR). These companies were identified through The Americas’ Fastest-Growing Companies 2023 list by the Financial Times. million and $38.8 million, respectively, as compared to $17.6

Genetics 111

Genetics Vaccination Vaccine DNA 111

pharmaphorum

AUGUST 23, 2022

To understand how quickly the industry responded, one need only look at the development history of Moderna’s COVID-19 vaccine: the company took all of two days to transition from receiving the genetic sequence of the virus to creating a vaccine candidate.

Vaccination 134

Vaccination Vaccine Development Trials 134

XTalks

AUGUST 17, 2020

protein-based biologics) and vaccine treatments. protein-based biologics) : are those which bind to specific components (i.e. A growing area in the immunotherapy space is the development of biological modulators, which are genetically engineered proteins that target specific components of the immune system.

Protein 98

Protein Engineer Immune Response In-Vivo 98

XTalks

DECEMBER 22, 2021

RNA, and its protein-generating form messenger RNA (mRNA) discovered in 1961 , has quickly transitioned from being an obscure, finicky molecule that is difficult to work with, to becoming a significant cornerstone of therapeutic innovation in pharma and biotech. The RNA Revolution: From mRNA Vaccines to RNA Editing. RNA Therapeutics.

Life Science 98

Life Science RNA Vaccination Vaccine 98

pharmaphorum

JANUARY 10, 2022

On the back of the approvals for Pfizer/BioNTech and Moderna, suddenly there is a large amount of interest from big pharma companies to get involved in the mRNA space. This not only allowed Pfizer to establish a COVID-19 vaccine but the company also recently announced that it had begun a study testing an mRNA flu vaccine.

RNA 111

RNA Vaccination Vaccine Pharma Companies 111

pharmaphorum

DECEMBER 21, 2020

As it’s just a messenger molecule, it does not affect the body’s own genetic code when it is injected as a vaccine – but what it does do is instruct cells to code for copies of a certain protein. In this case that is the “spike” protein seen on the surface of the coronavirus that it uses to invade host cells.

Vaccination 111

Vaccination Vaccine Doctors Doctor 111

Delveinsight

DECEMBER 2, 2020

Smoking – Cigarette smoking, coupled with the genetic factor, can increase the risk of developing Rheumatoid Arthritis. The blood test for Rheumatoid Arthritis considers factors such as Erythrocyte Sedimentation Rate (ESR), Anti-Cyclic Citrullinated Peptide, C-Reactive Protein (CRP), and many others.

Marketing 60

Marketing Hormones Antibody Development 60

XTalks

JANUARY 6, 2025

RNA-Based Therapeutics RNA molecules have emerged as promising therapeutic agents due to their ability to precisely target undruggable proteins or molecules, often with minimal side effects. Furthermore, CRISPR/Cas9 presents a promising avenue for overcoming genetic diseases in the near future. percent from 2022 to 2030.

Gene Therapy 111

Gene Therapy RNA Gene Editing Gene 111